Prohibited substance is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Among the many varieties of microorganisms, relatively few cause disease in otherwise healthy individuals. Infectious disease results from the interplay between those few pathogens and the defenses of the hosts they infect. The appearance and severity of disease resulting from any pathogen depend upon the ability of that pathogen to damage the host as well as the ability of the host to resist the pathogen. However, a host's immune system can also cause damage to the host itself in an attempt to control the infection. Clinicians, therefore, classify infectious microorganisms or microbes according to the status of host defenses – either as primary pathogens or as opportunistic pathogens.
==== Other chemistry and biochemistry ==== Amalgam (chemistry), represented in medieval alchemical texts with "aaa" Asymmetric allylic alkylation α-Aminoadipate pathway, for the synthesis of the amino acid L-lysine AAA proteins (ATPases Associated with various cellular Activities)
== Applications == If an oscillating U-tube is filled with water and pistons are placed at each end, pressure exerted by the left piston will be transmitted throughout the liquid and against the bottom of the right piston. (The pistons are simply "plugs" that can slide freely but snugly inside the tube.) The pressure that the left piston exerts against the water will be exactly equal to the pressure the water exerts against the right piston
Sources: en.wikipedia.org
DEAH-box helicase 8, is a protein that in humans is encoded by the DHX8 gene. This protein is member of the DEAH box polypeptide family. The main characteristic of this group is their conserved motif DEAH (Asp- Glu- Ala- His). A wide range of RNA helicases belongs to this family. Specifically, DHX8 acts as an ATP-dependent RNA helicase involved in splicing and the regulation of the releasing of spliced mRNAs from spliceosomes out of the nucleus. Published studies have shown the consequences of DHX8 mutations, some of them are critical for biological processes such as hematopoiesis and are related to some diseases.
H+ (hydron) and OH− (hydroxide). Singly charged monatomic (i.e., monovalent) ions like Na+, K+, and Cl−. Doubly charged monatomic (i.e., divalent) ions like Ca2+ and Mg2+. Polyatomic inorganic ions like SO42− and PO43−. Organic bases, usually molecules containing the functional group of ammonium, −N+R2H. Organic acids, often molecules containing −COO− (carboxylate) functional groups. Biomolecules that can be ionized: amino acids, peptides, proteins, etc. Along with absorption and adsorption, ion exchange is a form of sorption. Ion exchange is a reversible process, and the ion exchanger can be regenerated or loaded with desirable ions by washing with an excess of these ions.
Valerie Joy Beynon. For services to the community in Cobham, Surrey. Elizabeth Kay Billington. Chair, Kushti Bok and Vice-Chair, Dorset Council Gypsy Traveller Forum. For services to the Gypsy and Traveller Community in Dorset. William Archibald Bingham. Chair, Newcastle and Mourne Cancer Research Committee. For services to Cancer Research Fundraising in County Down. Chandra Shekhar Biyani. Consultant Urological Surgeon, Leeds Teaching Hospitals NHS Trust. For services to Medical Education. Reverend Christine Fiona Blackman. For services to the community in Reading, Berkshire. Derek John Bland. For services to the community in Northamptonshire. Roberta Vivian Lindsay Blyth. For services to the community in Roade, Northamptonshire. Winifred Patricia Bownes. Volunteer Coordinator, Cookstown Monday Club. For services to the community in Cookstown, County Tyrone. Mary Boyes. Cleaner, North Shore Academy, Stockton-on-Tees. For services to Education. John Robert Boyne-Aitken. For services to Heritage Crafts. Evelyn Lettita Bracey. For services to the community in Wantage, Oxfordshire. Paul Mark Brackley. Community First Responder, Oundle Community First Responders. For services to the community in Oundle and North Northamptonshire. Christopher Samuel Bradbury. For services to the community in Reedham, Norfolk. Moira Jeanette Brock. Founder and Principal, La Danse Fantastique. For services to Young People in Basildon, Essex. Anna Theresa Margaret Brown. For services to the NHS and to the community in the London Borough of Richmond-upon-Thames. Dennis Sydney Brown.
Labcorp Holdings Inc., operating under the brand name Labcorp, headquartered in Burlington, North Carolina, provides laboratory services used for diagnosis and healthcare decisions. It operates one of the largest clinical laboratory networks in the world and has operations in over 100 countries; although its operations are primarily in the U.S. Its Diagnostics Laboratories segment operates 2,000 patient service centers with more than 6,000 in-office phlebotomists in the United States. In addition to healthcare testing such as oncology testing, human immunodeficiency virus (HIV) genotyping and phenotyping, it provides testing for: employment, DNA testing to determine parentage and to determine immigration eligibility, environmental issues, wellness, toxicology, pain management, and medical drug monitoring. It also provides 50 tests that patients can complete at home. It processes over 160 million tests per year. Approximately 10% of this segment’s revenue are from the U.S. Medicare health insurance program. Its Biopharma Laboratory Services segment provides drug development, medical device and diagnostic development services to pharmaceutical, biotechnology, medical device, and diagnostic companies. In 2023, this division provided support to 84% of the new drugs and therapeutic products approved by the Food and Drug Administration. Labcorp performs its largest volume of specialty testing at its Center for Esoteric Testing in Burlington, North Carolina.
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.